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Abstract
Objectives—Eosinophilic esophagitis (EoE) has rapidly become a major cause of upper GI 
morbidity, but health care costs related to EoE have not been described. This study aimed to 
estimate EoE-related health care costs and utilization in the United States.
Methods—We performed a study of health care utilization of EoE cases compared to age- and 
sex-matched controls using administrative claims data, representative of the commercially insured 
population in the U.S. Cases of EoE were identified using a previously validated definition. We 
assessed inpatient, outpatient, emergency department, outpatient prescription, and endoscopy-
related costs for patients with EoE, and estimated total costs related to EoE extrapolated to the 
U.S. population.
Results—We identified 8,135 cases of EoE and 32,540 controls. The median total annual cost 
per EoE case was $3,304 compared to $1,001 for controls (p<0.001). For EoE, median costs 
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included $2,508/year for outpatient visits, $157 for endoscopies, and $325 for pharmacy claims, 
compared to $699, $0, and $76 for controls (p<0.001 for all). The overall median costs associated 
with EoE were $2,302/year/patient. Total costs in the U.S. ranged from $503 million to $1.36 
billion/year, depending on the prevalence estimate, with costs attributable to EoE ranging from 
$350-$947 million/year.
Conclusions—Patients with EoE have an estimated annual health care cost of as much as $1.4 
billion in the U.S. This represents a remarkable burden of disease for an entity that was essentially 
unknown two decades ago. These cost data can be used by policy makers to guide resource 
allocation.
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Introduction
Eosinophilic esophagitis (EoE) is a recently recognized clinicopathologic condition that has 
become increasingly common and is associated with upper gastrointestinal morbidity in both 
children and adults (1, 2). It is currently defined as an allergic/immune-mediated disease 
characterized clinically by symptoms of esophageal dysfunction and histologically by a 
marked eosinophilic infiltrate in the esophageal mucosa in the absence of other competing 
causes of esophageal eosinophilia (3, 4).
Estimating the prevalence of EoE at the national level was made possible after the 2008 
approval of an International Classification of Diseases, 9th Revision (ICD-9) code for EoE 
(530.13). Using this, we recently estimated that the prevalence of EoE in the United States, 
among children and adults between the ages of 0-64, is approximately 57 per 100,000 (5).
While the absolute numbers of patients affected by EoE are important, these numbers alone 
do not quantify the burden of disease attributable to EoE. To date, the healthcare utilization 
costs and patterns of use for patients diagnosed with EoE have not been previously 
described. The aims of the present study were to estimate EoE-related health care costs and 
utilization in the U.S. and to characterize the relative increase in costs and utilization for 
patients with EoE as compared to the general population.
Methods
Study design and data source
We performed a matched, case-control analysis using the IMS LifeLink® PharMetrics 
Health Plan Claims Database (IMS Health Inc, Watertown, MA) to characterize health care 
utilization and costs for EoE cases and controls. The database contains longitudinal, 
integrated, fully adjudicated medical and pharmaceutical claims for more than 75 million 
individuals from more than 80 health plans and has been shown to be representative of a 
U.S. national commercially insured population (6, 7). We analyzed data collected from 
January 1, 2009 through December 31, 2010. We restricted selection of cases and controls to 
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those patients age 0-64 who were continuously enrolled throughout this time period and 
whose benefit plan included prescription coverage.
Case and control selection
EoE cases were defined as patients with documentation of at least one instance of the ICD-9 
code 530.13. We previously validated a single instance of this code for diagnosis of EoE by 
using health plan claims records among commercially insured patients (8). Because we 
found that this case definition had high specificity (>99%) but a low sensitivity (37%), we 
performed pre-planned sensitivity analyses (see below). Controls were randomly selected 
from the enrollees meeting study inclusion criteria and were age- and sex-matched in a 4:1 
ratio to EoE cases.
Statistical analysis
We estimated total, all cause costs and claims for EoE patients both in sum and relative to 
controls. In this database, both charges and allowed costs are provided. For the purposes of 
this analysis, we used allowed costs, which represent the amount covered by the insurance 
provider plus the patient liability (e.g. co-pay, deductible, co-insurance).
We also characterized the costs and number of claims for EoE cases and controls for several 
types of services of interest. Specifically, we summed the total number of claims and costs 
(all cause) for inpatient, outpatient, and emergency department services by patient and then 
obtained the mean and median claims and costs for service for cases and for controls. We 
also calculated the total mean and median number of claims and costs for outpatient 
prescriptions and for upper endoscopies. Claims for upper endoscopies were identified by 
Current Procedural Terminology (CPT) codes (Supplementary Table 1). We also evaluated 
costs and claims for EoE patients with and without concomitant allergic conditions as 
identified from ICD-9 diagnostic codes (Supplementary Table 1).
We assessed for statistically significant differences in costs and claims for EoE patients 
versus controls overall and by service type and evaluated for differences by age and sex. We 
also calculated the difference in costs between the case and the control groups to represent 
the health care utilization attributable to EoE and conducted a sensitivity analysis for these 
total costs based on a range of possible prevalences. Details of the statistical analyses are 
described in the Supplementary Material (available online).
This study was designated as exempt from review by the UNC Institutional Review Board.
Results
A total of 8,135 cases of EoE and 32,540 sex and age-matched controls met inclusion 
criteria (Table 1). The mean age was 35.5 ± 16.8 years, 21% were < 18 years of age, and 
65% were male. As expected with the matching strategy, cases and controls were identical 
in their distribution of age and sex. Relative to controls, a higher proportion of cases resided 
in the Midwest region and a smaller proportion of cases resided in the East. A somewhat 
smaller proportion of cases had received insurance coverage through Medicaid (1.8% versus 
6.7%) (Table 1).
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Costs and claims attributable to EoE
For the 2 year period analyzed, all cause total cost of health care services and the total 
number of claims was significantly higher for EoE cases than controls (Table 2). Median 
total costs were $6,608 for cases compared to $2,003 for controls (p < 0.001), and median 
number of claims for cases was double that of controls (67 versus 34; p < 0.001). These data 
are right-skewed due to small numbers of patients having significantly higher claims and 
costs relative to most patients. However, the higher costs and number of claims associated 
with EoE was also observed when comparing means (Table 2). Stratification of patients by 
age (<18 versus 18-64) indicated that for cases, the costs and number of claims was higher 
among the pediatric population (Table 2).
Furthermore, we found the relative difference in costs between cases and controls was 
significantly higher for younger patients, and the differences were more pronounced for 
males. For costs for males, we found that for each 5 year increase in age there was a 12 
percent decrease (95% CI: 13%, 11%) in the costs for cases relative to controls. Among 
females, there was a 9 percent decrease (95% CI: 11%, 8%). Similarly, for total claims for 
males, for each 5 year increase in age there was a 17 percent decrease (95% CI: 19%, 15%) 
in the number of claims and for females there was a 13 percent decrease (95% CI: 16%, 
11%). Moreover, relative to patients in the oldest age group, the difference between cases 
and controls was progressively greater as age decreased. This was true among both males 
and females (Figure 1).
There were 3,227 (39.7%) EoE cases with concomitant claims for an allergic condition. The 
median, all cause total costs for cases with allergic disease was higher than for those without 
of allergic disease ($10,584 versus $4,190; p < 0.01). Similarly, the median number of 
claims was higher for EoE patients with allergic disease (106 versus 43; p < 0.01).
Inpatient, outpatient, and emergency room services
Evaluation of inpatient, outpatient, and emergency department services identified similar 
patterns of higher costs and numbers of claims for EoE patients, although most subjects 
(EoE cases and controls) had no inpatient claims during the study period (Table 3). Of note, 
the inpatient costs for pediatric controls was low, reflecting that most children are healthy 
and do not require hospital admission.
For outpatient services, the number of claims and allowed costs were significantly higher in 
EoE cases than in controls (Table 4). The difference between cases and controls was highest 
among children, where the median costs for cases was $6,327 versus $752 for controls (p < 
0.001). Similarly, the difference in number of claims was highest among children.
While few patients obtained emergency room department services in the 2-year study 
period, claims and costs were still significantly higher in EoE cases than in controls 
(Supplementary Table 2).
Prescriptions
The median number of prescription claims was significantly higher for EoE cases than 
controls (Table 5). The median allowed costs for outpatient prescriptions were generally 
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about 4-fold higher for EoE cases versus controls overall ($650 vs $151; p < 0.001) and 
these differences persisted after stratification by age (Table 5).
Upper endoscopies
The number of claims and costs for upper endoscopies was significantly higher for EoE 
cases as compared to controls (Supplementary Table 3). This yielded increased overall 
median costs for the EoE cases ($331 vs $0; p < 0.001) and these differences persisted after 
stratification by age (Supplementary Table 3).
Total burden of disease attributable to EoE
The annual, all cause median cost per EoE patient was $3,304, and $1,001 for non-cases. 
Therefore, the EoE-attributable annual median cost for EoE patients is $2,302. Based on 
previously described prevalence estimates (5), we extrapolated total estimated costs for EoE 
in the U.S.. A lower bound (56.7 cases/100,000) estimate of the total annual health care 
costs related to EoE is $502,710,208 per year. The lower bound on total excess costs for 
EoE patients is $350,329,980 per year. Extrapolating to the upper bound estimate (153.2 
cases/100,000), the total costs for EoE patients could be as high as $1,358,677,488 billion, 
with $946,633,044 million costs in excess of baseline costs.
Discussion
Over the past two decades, eosinophilic esophagitis has transformed from a case-reportable 
disease to a major cause of upper GI morbidity (9-15) with an estimated prevalence of 
0.5-1/1000 (5, 16-21). With EoE becoming more common, there is a pressing need to assess 
the disease burden of EoE as measured by heath care costs, claims, and utilization.
In this study, we used a large administrative database to estimate, for the first time, the costs 
associated with having EoE. The results were striking, but not necessarily surprising. EoE 
diagnosis and treatment is expensive, and represents a substantial health care burden. 
Depending on the prevalence estimate used, the total costs attributable to having a 
diagnostic code for EoE range from more than $500 million to more than $1.3 billion per 
year. Moreover, when the baseline costs from a control population are removed, 
approximately two-thirds of these costs remain directly attributable to EoE. Interestingly, 
costs and claims were higher for EoE patients with concomitant allergic diseases, but costs 
for EoE patients without allergic disease were still higher than controls.
Putting these values into context illustrates that this is a remarkable level of expenditures for 
EoE. Based on a recent analysis of the burden of all GI illnesses, the costs attributable to 
EoE are roughly of the same order of magnitude as hospital-related costs for acute 
appendicitis ($1.4 billion), GI hemorrhage ($1.1 billion), Clostridium difficile infection ($1.1 
billion), and inflammatory bowel disease ($1 billion) (22). The only cost data related to EoE 
of which we are aware were presented in abstract form and were derived from the 
Nationwide Inpatient Sample (23). However, this study is not directly comparable to ours 
for several reasons: the data source was based on discrete hospitalizations, not longitudinal 
inpatient and outpatient records; the study population included only patients hospitalized for 
esophageal foreign body impactions; and the study analyzed hospital charges, not costs.
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The high costs for patients with EoE reflected in this analysis are consistent with the current 
management paradigm for EoE. For some patients, diagnosis and monitoring of the initial 
treatment course (often with expensive topical corticosteroids) will require three 
endoscopies over the course of 4-6 months (1). Additionally, EoE is primarily managed in 
the outpatient setting, explaining the low number of inpatient claims that we found. The 
higher costs in children are also understandable, as children undergoing endoscopy often 
require a hospital-based procedure unit and general anesthesia.
There are some limitations of this study. First, because we used an administrative database, 
we had limited information pertaining to certain demographic and clinical variables such as 
race, socioeconomic status, and practice setting. Second, misclassification of disease status 
is possible. Administrative claims lack or histologic data, and there are no diagnostic codes 
for proton pump inhibitor-responsive esophageal eosinophilia. If there were EoE cases who 
did not truly have EoE, their individual costs could either be higher or lower, depending on 
the condition that led them to seek treatment. However, we previously found that the ICD-9 
code for EoE has a high specificity but low sensitivity (8), which would likely lead to 
underestimating the number of EoE cases and therefore lower cost estimates. Given the 
relative rarity of EoE, misclassification of disease-free status among controls seems 
unlikely. Third, because of the database used, our cost estimates are restricted to those 
individuals aged 0-64 with commercial insurance and prescription drug coverage, and are 
not necessarily generalizable to the under- or uninsured. However, the vast majority of EoE 
cases are in this age range. There were also a higher proportion of controls with Medicaid as 
compared to cases. While this could inflate the costs for cases, it should not impact the 
number of claims. A sensitivity analysis restricting the case and control sample to 
subscribers with no Medicaid coverage did not materially change the results ($6,602 for 
cases vs $2,109 for controls; p<0.001). Finally, while comparison to controls provides an 
estimate of healthcare utilization associated with EoE, we cannot discern from these data 
whether thes increase in costs for EoE patients with allergic disease represent costs 
attributable to the allergic disease itself, varying treatment approaches for EoE patients with 
atopy (ie food elimination diets with expensive follow-up endoscopic monitoring), or a more 
difficult to treat and costly phenotype of EoE.
Despite these potential limitations, this is a very large claims database that has been 
demonstrated to be representative of all patients in the U.S. with commercial insurance, and 
allowed a comprehensive analysis of a large number of cases (6, 7). We used actual costs, 
including allowed payouts by insurances and subscriber liability, instead of charges, so our 
results closely reflect true expenditures. We had the granularity to perform a detailed 
analysis of claims, sites of care, and pharmacy claims. Finally, we not only assessed the total 
costs related to EoE diagnostic codes, but calculated the costs directly attributable to EoE or 
EoE-related comorbidity by including matched control subjects in the analysis.
Our study design captured both incident and prevalent cases, which would include a 
proportion of patients who might have stable disease and require minimal ongoing 
evaluation. Therefore, the utilization estimates presented in this study provide the best-
known estimate of the healthcare burden for EoE disease given current standards for 
diagnosis and treatment. However, our study could not account for costs related to dietary 
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therapy (either more expenses for hypoallergenic food products or for elemental formulas, 
neither of which are reimbursed by most insurers), for costs related to home health care, or 
for costs related to work absenteeism because of procedures or office visits for either and 
their caretakers.
In conclusion, this matched, case-control analysis of a large administrative database found 
that EoE has an estimated annual health care cost between $0.5 and $1.4 billion in the U.S. 
This represents a remarkable burden of disease for an entity that was essentially unknown 
two decades ago. These cost data reflect current management strategies, which rely on upper 
endoscopy with biopsies for disease diagnosis and management. These data can also be used 
by policy makers for planning and to inform resource allocation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Relative all cause costs for EoE patients versus controls by age and sex. Data source: IMS 
LifeLink® PharMetrics Health Plan Claims Database, January 2001-November 2011, IMS 
Health Incorporated. All Rights Reserved.
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